STANS, Switzerland,
Feb. 25, 2021 /PRNewswire/
-- NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW), a
clinical-stage pharmaceutical company focused on the discovery and
development of innovative therapies for patients with rare and
complex central nervous system disorders, announces that
Alex Zwyer, Chief Executive Officer
and Co-Founder, is scheduled to present at the following upcoming
investor conferences:
- Livingston Securities Healthcare and Emerging Growth CEO Series
on Thursday, February 25, 2021 at
11:30am Eastern Time (5:30pm CET).
- Maxim 2021 Emerging Growth Virtual Conference hosted by M-Vest
on March 17, 2021. The Company's
presentation for this conference will be available on M-Vest
following the conference.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage
biopharmaceutical company led by an experienced management team
with a track record of developing and repurposing product
candidates to treat rare and complex central nervous system
disorders. The Company's lead product candidate, Quilience® is a
proprietary controlled release formulation of mazindol (mazindol
CR), and is being developed for the treatment of narcolepsy.
Mazindol is a triple monoamine reuptake inhibitor and partial
orexin receptor 2 agonist, which was used for many years to treat
patients diagnosed with narcolepsy in compassionate use programs.
NLS completed a phase 2 study in the U.S. evaluating mazindol CR in
adult subjects with ADHD. The study met all primary and secondary
endpoints and was well-tolerated. Quilience® has received Orphan
Drug Designations both in the U.S. and in Europe for the
treatment of narcolepsy.
Corporate contact
Alex
Zwyer, CEO: +41 41 618 80 00
Investor Relations contact
David Moskowitz: +1 202-280-0888
www.nlspharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/nls-pharmaceutics-to-participate-in-upcoming-investor-conferences-301235488.html
SOURCE NLS Pharmaceutics Ltd.